Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries.

Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, Leufkens HG.

Health Policy. 2012 Jan;104(1):76-83. doi: 10.1016/j.healthpol.2011.10.011. Epub 2011 Nov 12.

PMID:
22079753
[PubMed - indexed for MEDLINE]
2.

Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study.

Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Laing RO, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):265-71. doi: 10.1002/pds.2093. Epub 2011 Jan 10.

PMID:
21351308
[PubMed - indexed for MEDLINE]
3.

The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.

Jönsson B, Kobelt G, Smolen J.

Eur J Health Econ. 2008 Jan;8 Suppl 2:S61-86.

PMID:
18097697
[PubMed - indexed for MEDLINE]
4.

Estimated medication costs of primary TNFα antagonist failure in patients with rheumatoid arthritis.

Rose E, Lequerré T, Pouplin S, Daragon A, Le Loët X, Vittecoq O.

Joint Bone Spine. 2012 Jul;79(4):421-2. doi: 10.1016/j.jbspin.2012.01.017. Epub 2012 Apr 17. No abstract available.

PMID:
22512937
[PubMed - indexed for MEDLINE]
5.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Erratum in: Lancet. 2009 Oct 24;374(9699):1422.

PMID:
19560810
[PubMed - indexed for MEDLINE]
6.

Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

Richard-Miceli C, Dougados M.

BioDrugs. 2001;15(4):251-9. Review.

PMID:
11437690
[PubMed - indexed for MEDLINE]
7.

Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.

Spalding JR, Hay J.

Pharmacoeconomics. 2006;24(12):1221-32.

PMID:
17129076
[PubMed - indexed for MEDLINE]
8.

The case of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis: a budget impact analysis.

Sørensen J, Andersen LS.

Pharmacoeconomics. 2005;23(3):289-98.

PMID:
15836009
[PubMed - indexed for MEDLINE]
9.

Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.

Doan QV, Chiou CF, Dubois RW.

J Manag Care Pharm. 2006 Sep;12(7):555-69. Review.

PMID:
16981801
[PubMed - indexed for MEDLINE]
Free Article
10.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

PMID:
17049139
[PubMed - indexed for MEDLINE]
Free Article
11.
12.

[Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].

Curković B, Babić-Naglić D, Morović-Vergles J, Anić B, Grazio S.

Reumatizam. 2008;55(1):22-5. Croatian. Erratum in: Reumatizam. 2009;56(1):58.

PMID:
19024266
[PubMed - indexed for MEDLINE]
13.

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.

Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1147-52.

PMID:
20074482
[PubMed - indexed for MEDLINE]
14.

Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009.

Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L; ARTIS Study Group.

Scand J Rheumatol. 2011 Jan;40(1):8-15. doi: 10.3109/03009742.2010.493895. Epub 2010 Oct 18.

PMID:
20955087
[PubMed - indexed for MEDLINE]
15.

[TNFalpha inhibitors for the treatment of rheumatoid arthritis].

Sany J, Kaiser MJ.

Ann Med Interne (Paris). 2002 Feb;153(1):34-40. Review. French.

PMID:
11994688
[PubMed - indexed for MEDLINE]
16.

[Profile of use of anti tumor necrosis factor in Colombian patients].

Machado J, Moncada JC, Pineda R.

Biomedica. 2011 Jun;31(2):250-7. doi: 10.1590/S0120-41572011000200013. Spanish.

PMID:
22159542
[PubMed - indexed for MEDLINE]
Free Article
17.

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.

Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Curr Med Res Opin. 2007 Aug;23(8):1749-59.

PMID:
17588306
[PubMed - indexed for MEDLINE]
18.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
[PubMed - indexed for MEDLINE]
19.

Patient's access to healthcare and treatment in rheumatoid arthritis: the views of stakeholders in Portugal.

Laires PA, Mesquita R, Veloso L, Martins AP, Cernadas R, Fonseca JE.

BMC Musculoskelet Disord. 2013 Sep 25;14:279. doi: 10.1186/1471-2474-14-279.

PMID:
24067096
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.

PMID:
18311816
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk